These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reappraisal of the clinical effect of mepolizumab. Lipworth BJ; Jabbal S Lancet Respir Med; 2017 Jun; 5(6):e20. PubMed ID: 28664852 [No Abstract] [Full Text] [Related]
3. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma. Kelly EA; Esnault S; Liu LY; Evans MD; Johansson MW; Mathur S; Mosher DF; Denlinger LC; Jarjour NN Am J Respir Crit Care Med; 2017 Dec; 196(11):1385-1395. PubMed ID: 28862877 [TBL] [Abstract][Full Text] [Related]
4. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Pouliquen IJ; Kornmann O; Barton SV; Price JA; Ortega HG Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1015-27. PubMed ID: 26445140 [TBL] [Abstract][Full Text] [Related]
5. No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Oldhoff JM; Darsow U; Werfel T; Bihari IC; Katzer K; Laifaoui J; Plötz S; Kapp A; Knol EF; Bruijnzeel-Koomen CA; Ring J; de Bruin-Weller MS Int Arch Allergy Immunol; 2006; 141(3):290-4. PubMed ID: 16931891 [TBL] [Abstract][Full Text] [Related]
6. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833 [TBL] [Abstract][Full Text] [Related]
9. Mepolizumab in the treatment of severe eosinophilic asthma. Fainardi V; Pisi G; Chetta A Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083 [TBL] [Abstract][Full Text] [Related]
10. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242 [TBL] [Abstract][Full Text] [Related]
11. Mepolizumab for Eosinophilic COPD. Shahlavi‑Monavvar P; Mobasher-Jannat A N Engl J Med; 2018 Feb; 378(7):681. PubMed ID: 29446292 [No Abstract] [Full Text] [Related]
12. Mepolizumab for Eosinophilic COPD. Xia Y; Li W; Shen H N Engl J Med; 2018 Feb; 378(7):680-1. PubMed ID: 29446291 [No Abstract] [Full Text] [Related]
13. Mepolizumab for Eosinophilic COPD. Sciurba FC; Bradford ES; Pavord ID N Engl J Med; 2018 Feb; 378(7):681-683. PubMed ID: 29443666 [No Abstract] [Full Text] [Related]
14. Mepolizumab: A Review in Eosinophilic Asthma. Deeks ED BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938 [TBL] [Abstract][Full Text] [Related]
15. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549 [TBL] [Abstract][Full Text] [Related]
16. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Oldhoff JM; Darsow U; Werfel T; Katzer K; Wulf A; Laifaoui J; Hijnen DJ; Plötz S; Knol EF; Kapp A; Bruijnzeel-Koomen CA; Ring J; de Bruin-Weller MS Allergy; 2005 May; 60(5):693-6. PubMed ID: 15813818 [TBL] [Abstract][Full Text] [Related]
18. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. Ortega H; Li H; Suruki R; Albers F; Gordon D; Yancey S Ann Am Thorac Soc; 2014 Sep; 11(7):1011-7. PubMed ID: 24983709 [TBL] [Abstract][Full Text] [Related]